Perrigo

Notice of Proposed Settlement and Plan of Allocation Involving Purchasers of Perrigo Common Stock from April 21, 2015 through May 2, 2017 and Owners of Perrigo Common Stock as of November 12, 2015

Retrieved on: 
Venerdì, Maggio 17, 2024
Prejudice, Perrigo, Class, CLASS, Settlement, Post office box, Lead, Person, Motion, Agreement, Plan, Summons, Claim, Court, Tel Aviv Stock Exchange, District court, Magistrate, Hearing, Action

Copies of the Settlement Notice and Claim Form can also be downloaded from the website for the Action, www.PerrigoSecuritiesLitigation.com .

Key Points: 
  • Copies of the Settlement Notice and Claim Form can also be downloaded from the website for the Action, www.PerrigoSecuritiesLitigation.com .
  • Please do not contact the Court, the Clerk’s office, Perrigo, any other Defendant in the Action, or their counsel regarding this notice.
  • All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed the Claims Administrator or Lead Counsel.
  • Requests for the Settlement Notice and Claim Form should be made to:

Perrigo Announces Quarterly Dividend

Retrieved on: 
Mercoledì, Maggio 1, 2024
Consumer, Perrigo, PRGO

DUBLIN, May 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024.

Key Points: 

DUBLIN, May 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024.

WPP First Quarter Trading Update

Retrieved on: 
Giovedì, Aprile 25, 2024
Professional Services, Marketing, Advertising, Communications, Finance, Public Relations, Investor Relations, Cloud, VML, The Coca-Cola Company, NHS, Pandemic, Daiichi Sankyo, Risk, WPP plc, Capital market, Google Cloud, Transplant, Epidemic, WPP, Medicine, Terrorism, FX, AstraZeneca, Breast cancer, Knowledge, Attack, Outline of health sciences, Super Bowl, Uncertainty, HCM, Workforce, Generative, Blood, Gemini, Travel, Artificial intelligence, Perrigo, Gold, Creativity, FY, Ogilvy, Disclosure, LFL, Synthetic media, Failure, WARC, Growth

During the quarter we continued to invest in WPP Open, our intelligent marketing operating system powered by AI, as part of our annual investment of £250m in AI, data and tech.

Key Points: 
  • During the quarter we continued to invest in WPP Open, our intelligent marketing operating system powered by AI, as part of our annual investment of £250m in AI, data and tech.
  • WPP was proud to be recognised by the NVIDIA Partner Network as the Industry Innovation Partner of the Year in EMEA.
  • During the quarter, WPP topped the WARC Media 100 for the seventh year running and topped the WARC Creative 100 for the second consecutive year.
  • Proportion of WPP revenue less pass-through costs in Q1 2024; table made up of clients representing 77% of WPP total revenue less pass-through costs.

Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024

Retrieved on: 
Martedì, Aprile 23, 2024
Consumer, Perrigo, ID, International, EDT, PRGO

DUBLIN, April 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024 financial results on Tuesday, May 7th, 2024, and host a conference call beginning at 8:30 A.M. (EDT).

Key Points: 
  • DUBLIN, April 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024 financial results on Tuesday, May 7th, 2024, and host a conference call beginning at 8:30 A.M. (EDT).
  • The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-664-6383, International 416-764-8650, and reference ID # 910565.
  • A taped replay of the call will be available beginning at approximately 12:00 P.M. (EDT) Tuesday, May 7, until midnight Wednesday, May 15, 2024.
  • To listen to the replay, dial 888-390-0541, International 416-764-8677, and use access code 910565#.

Opill and WNBA Team Up for Groundbreaking Partnership

Retrieved on: 
Martedì, Aprile 9, 2024
Consumer, National Basketball Association, Organization, Birth, Sport, Health equity, Social justice, Partnership, Pharmacy, Draft, NBA scoring leaders, Student, Perrigo, OTC, WNBA draft, WNBA, FDA, Health education, Food

GRAND RAPIDS, Mich. and NEW YORK, April 9, 2024 /PRNewswire/ -- Today, Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced that Opill® — the first-ever daily birth control pill available without a prescription in the U.S. — and the Women's National Basketball Association (WNBA) have entered a multi-year partnership that focuses on building confidence, strength and health equity, all of which closely align with both organizations' core priorities.

Key Points: 
  • "Opill® is changing the game in reproductive health, just like the WNBA's game-changing role in sports and pop culture," said Leila Bahbah, Perrigo U.S. Women's Health Brand Lead.
  • Opill® will tip off the relationship as an Associate Partner of the 2024 WNBA Draft presented by State Farm on April 15 in Brooklyn, New York.
  • This season, the WNBA is concentrating its social justice efforts into two areas: civic engagement and reproductive health advocacy.
  • Opill® and the WNBA are also collaborating on a program to reach students on college campuses nationwide.

Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

Retrieved on: 
Lunedì, Marzo 25, 2024
Biotechnology, Growth, Associated, Horizon Therapeutics, Executive, Patient, Business development, Acquisition, Élan, Inflammation, University College Cork, Commerce, Perrigo, Investment, Corporate development, Autoimmunity, Management

“This newly created position reflects the important inflection point at which we at Ardelyx find ourselves: Envisioning and building our future following the successful launch of two first-in-class medicines within the past two years,” said Mike Raab, president and chief executive officer of Ardelyx.

Key Points: 
  • “This newly created position reflects the important inflection point at which we at Ardelyx find ourselves: Envisioning and building our future following the successful launch of two first-in-class medicines within the past two years,” said Mike Raab, president and chief executive officer of Ardelyx.
  • “It is a pleasure to welcome Mike at this critical period of our growth.
  • His experience and expertise defining and advancing corporate strategies along with his proven track record of delivering value-accretive collaborations and transactions strengthen our leadership team and position us for success.
  • Mr. Kelliher began his career in banking, public accounting and corporate finance and holds a Bachelor of Commerce degree from the University College Cork (Ireland).

As Opill Enhances Women's Reproductive Choices Dr. Mary Jane Minkin Highlights Key Differences Between the Progesterone-Only Opill and Traditional Estrogen-Based Contraceptives “The Pill”

Retrieved on: 
Lunedì, Marzo 11, 2024
Health, FDA, Consumer, Women, Baby, Maternity, General Health, Pharmaceutical, Mother, Birth, Education, OBGYN, Combined oral contraceptive pill, Condom, Risk, Diabetes, Ovulation, Stroke, History, Sale, News, Fertility, Splenic infarction, Smoke, Perrigo, Woman, OTC, Pill, Cancer, Breast cancer, Safety, Progesterone, MUST, Migraine, Birth control

Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.

Key Points: 
  • Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.
  • "Education is key at this juncture to prevent an increase in unintended pregnancies in the coming months.
  • The Opill, significantly differs from the traditional birth control pill in that it is less effective at preventing ovulation when pills are missed or skipped for any reason.
  • The availability of the Opill OTC, or progesterone-only pill, is wonderful news for those women unable to take estrogen or 'The Pill.'

Lutris Pharma Appoints Life Sciences and Pharmaceutical Entrepreneur Moshe "Mori" Arkin to Its Board of Directors

Retrieved on: 
Lunedì, Aprile 1, 2024
Culture, EGFR, Organization, Philosophy, Education, History, Patient, Orphan, Left–right political spectrum, Growth factor, Acquisition, Perrigo, Quality of life, Psychology, Drug development, TEL, Food, Pharmaceutical industry

TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the appointment Moshe "Mori" Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.

Key Points: 
  • TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the appointment Moshe "Mori" Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.
  • "Mori is one of Israel's most successful life sciences and pharmaceutical entrepreneurs with an extraordinary background spanning decades in the industry," stated Antoni Ribas, M.D., Ph.D., Chairman and Founder of Lutris Pharma.
  • "Arkin Bio Ventures has been an investor in Lutris Pharma since its inception and has been a steadfast supporter of the Company, ever since.
  • In 2011, they formed the Arkin Family Foundation, which supports organizations and projects in education, arts and culture, welfare, healthcare, civil rights, and Jewish-Arab coexistence.

Lutris Pharma Appoints Life Sciences and Pharmaceutical Entrepreneur Moshe "Mori" Arkin to Its Board of Directors

Retrieved on: 
Lunedì, Aprile 1, 2024
Culture, EGFR, Organization, Philosophy, Education, History, Patient, Orphan, Left–right political spectrum, Growth factor, Acquisition, Perrigo, Quality of life, Psychology, Drug development, TEL, Food, Pharmaceutical industry

TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the appointment Moshe "Mori" Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.

Key Points: 
  • TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the appointment Moshe "Mori" Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.
  • "Mori is one of Israel's most successful life sciences and pharmaceutical entrepreneurs with an extraordinary background spanning decades in the industry," stated Antoni Ribas, M.D., Ph.D., Chairman and Founder of Lutris Pharma.
  • "Arkin Bio Ventures has been an investor in Lutris Pharma since its inception and has been a steadfast supporter of the Company, ever since.
  • In 2011, they formed the Arkin Family Foundation, which supports organizations and projects in education, arts and culture, welfare, healthcare, civil rights, and Jewish-Arab coexistence.

Perrigo Commences Shipments of Opill® to Retailers Nationwide, Empowering Millions to Enter a New Era of Reproductive Health Access in the United States

Retrieved on: 
Lunedì, Marzo 4, 2024
Melissa, Woman, FDA, OTC, Perrigo, Food, Transport, Family medicine, Pharmacy, MBA, Health savings account, American Medical Association, Pregnancy, FSA, Health, HSA, American College, MPH, Consumer, MSRP, PRGO, American Academy, Birth control

Additionally, Opill® will be available for purchase at Opill.com at a price of $49.99 for a three-month supply and $89.99 for a six-month supply.

Key Points: 
  • Additionally, Opill® will be available for purchase at Opill.com at a price of $49.99 for a three-month supply and $89.99 for a six-month supply.
  • "The availability of an oral contraceptive without a prescription is a truly groundbreaking milestone in reproductive health," said Melissa J. Kottke, MD, MPH, MBA, obstetrician-gynecologist in Atlanta, GA*.
  • Creating additional opportunities for contraceptive access is critical in helping people reach their reproductive goals."
  • * Melissa J. Kottke, MD, MPH, MBA served as a paid consultant during the FDA approval process for Perrigo in 2023.